Name | Number of supported studies | Average coverage | |
---|---|---|---|
classical monocyte | 19 studies | 26% ± 11% | |
macrophage | 16 studies | 27% ± 8% | |
myeloid cell | 12 studies | 27% ± 10% | |
monocyte | 9 studies | 22% ± 5% | |
microglial cell | 9 studies | 33% ± 10% | |
conventional dendritic cell | 8 studies | 29% ± 17% | |
dendritic cell | 8 studies | 31% ± 17% | |
type I pneumocyte | 7 studies | 28% ± 9% | |
T follicular helper cell | 6 studies | 21% ± 5% | |
regulatory T cell | 5 studies | 19% ± 4% | |
type II pneumocyte | 5 studies | 20% ± 3% | |
astrocyte | 5 studies | 21% ± 7% | |
neutrophil | 4 studies | 22% ± 5% | |
epithelial cell | 4 studies | 31% ± 14% | |
hepatocyte | 4 studies | 72% ± 23% | |
CD4-positive, alpha-beta memory T cell | 3 studies | 25% ± 11% | |
ciliated cell | 3 studies | 26% ± 7% | |
naive thymus-derived CD4-positive, alpha-beta T cell | 3 studies | 18% ± 2% | |
endothelial cell | 3 studies | 24% ± 2% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 4 studies | 21% ± 6% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 100% | 8413.11 | 226 / 226 | 99% | 53.84 | 400 / 406 |
lung | 100% | 4207.71 | 577 / 578 | 94% | 22.67 | 1086 / 1155 |
kidney | 97% | 2306.00 | 86 / 89 | 94% | 24.42 | 844 / 901 |
ovary | 97% | 2017.43 | 174 / 180 | 93% | 19.83 | 398 / 430 |
esophagus | 99% | 2991.33 | 1426 / 1445 | 90% | 14.22 | 164 / 183 |
skin | 89% | 1390.58 | 1615 / 1809 | 96% | 29.43 | 454 / 472 |
prostate | 98% | 1876.42 | 241 / 245 | 83% | 9.01 | 419 / 502 |
breast | 99% | 1832.37 | 454 / 459 | 79% | 9.36 | 880 / 1118 |
uterus | 100% | 2825.09 | 170 / 170 | 72% | 8.47 | 329 / 459 |
stomach | 94% | 2193.04 | 339 / 359 | 75% | 9.36 | 215 / 286 |
intestine | 100% | 3889.02 | 966 / 966 | 64% | 6.57 | 338 / 527 |
pancreas | 70% | 815.18 | 228 / 328 | 88% | 14.11 | 157 / 178 |
bladder | 100% | 1868.48 | 21 / 21 | 54% | 6.37 | 273 / 504 |
adrenal gland | 99% | 1473.34 | 256 / 258 | 42% | 5.82 | 97 / 230 |
brain | 49% | 542.74 | 1307 / 2642 | 88% | 9.59 | 620 / 705 |
thymus | 70% | 750.77 | 457 / 653 | 59% | 7.98 | 354 / 605 |
muscle | 100% | 15982.57 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 3942.72 | 241 / 241 | 0% | 0 | 0 / 0 |
adipose | 100% | 2630.43 | 1200 / 1204 | 0% | 0 | 0 / 0 |
peripheral blood | 95% | 11795.66 | 886 / 929 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 91% | 13.90 | 41 / 45 |
blood vessel | 90% | 1851.20 | 1198 / 1335 | 0% | 0 | 0 / 0 |
heart | 89% | 1154.56 | 763 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 86% | 26.00 | 25 / 29 |
eye | 0% | 0 | 0 / 0 | 75% | 9.73 | 60 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0042531 | Biological process | positive regulation of tyrosine phosphorylation of STAT protein |
GO_0097191 | Biological process | extrinsic apoptotic signaling pathway |
GO_0019221 | Biological process | cytokine-mediated signaling pathway |
GO_0010573 | Biological process | vascular endothelial growth factor production |
GO_0032722 | Biological process | positive regulation of chemokine production |
GO_0010536 | Biological process | positive regulation of activation of Janus kinase activity |
GO_0006953 | Biological process | acute-phase response |
GO_0072126 | Biological process | positive regulation of glomerular mesangial cell proliferation |
GO_0002384 | Biological process | hepatic immune response |
GO_0034097 | Biological process | response to cytokine |
GO_0050829 | Biological process | defense response to Gram-negative bacterium |
GO_0048661 | Biological process | positive regulation of smooth muscle cell proliferation |
GO_0038154 | Biological process | interleukin-11-mediated signaling pathway |
GO_0045669 | Biological process | positive regulation of osteoblast differentiation |
GO_0070120 | Biological process | ciliary neurotrophic factor-mediated signaling pathway |
GO_0070102 | Biological process | interleukin-6-mediated signaling pathway |
GO_0050731 | Biological process | positive regulation of peptidyl-tyrosine phosphorylation |
GO_0072540 | Biological process | T-helper 17 cell lineage commitment |
GO_0008284 | Biological process | positive regulation of cell population proliferation |
GO_0031018 | Biological process | endocrine pancreas development |
GO_0002548 | Biological process | monocyte chemotaxis |
GO_0002690 | Biological process | positive regulation of leukocyte chemotaxis |
GO_0032755 | Biological process | positive regulation of interleukin-6 production |
GO_0005896 | Cellular component | interleukin-6 receptor complex |
GO_0016324 | Cellular component | apical plasma membrane |
GO_0009897 | Cellular component | external side of plasma membrane |
GO_0043235 | Cellular component | receptor complex |
GO_0005576 | Cellular component | extracellular region |
GO_0005886 | Cellular component | plasma membrane |
GO_0070110 | Cellular component | ciliary neurotrophic factor receptor complex |
GO_0019970 | Molecular function | interleukin-11 binding |
GO_0019899 | Molecular function | enzyme binding |
GO_0070119 | Molecular function | ciliary neurotrophic factor binding |
GO_0042803 | Molecular function | protein homodimerization activity |
GO_0004897 | Molecular function | ciliary neurotrophic factor receptor activity |
GO_0004915 | Molecular function | interleukin-6 receptor activity |
GO_0004921 | Molecular function | interleukin-11 receptor activity |
GO_0005138 | Molecular function | interleukin-6 receptor binding |
GO_0019981 | Molecular function | interleukin-6 binding |
GO_0005515 | Molecular function | protein binding |
Gene name | IL6R |
Protein name | Interleukin 6 receptor Interleukin-6 receptor subunit alpha (IL-6 receptor subunit alpha) (IL-6R subunit alpha) (IL-6R-alpha) (IL-6RA) (IL-6R 1) (Membrane glycoprotein 80) (gp80) (CD antigen CD126) [Cleaved into: Soluble interleukin-6 receptor subunit alpha (sIL6R)] |
Synonyms | hCG_1810911 |
Description | FUNCTION: Part of the receptor for interleukin 6. Binds to IL6 with low affinity, but does not transduce a signal . Signal activation necessitate an association with IL6ST. Activation leads to the regulation of the immune response, acute-phase reactions and hematopoiesis . The interaction with membrane-bound IL6R and IL6ST stimulates 'classic signaling', the restricted expression of the IL6R limits classic IL6 signaling to only a few tissues such as the liver and some cells of the immune system. Whereas the binding of IL6 and soluble IL6R to IL6ST stimulates 'trans-signaling'. Alternatively, 'cluster signaling' occurs when membrane-bound IL6:IL6R complexes on transmitter cells activate IL6ST receptors on neighboring receiver cells (Probable). .; FUNCTION: [Isoform 1]: Signaling via the membrane-bound IL6R is mostly regenerative and anti-inflammatory (Probable). Drives naive CD4(+) T cells to the Th17 lineage, through 'cluster signaling' by dendritic cells (By similarity). .; FUNCTION: [Isoform 2]: Soluble form of IL6 receptor (sIL6R) that acts as an agonist of IL6 activity . The IL6:sIL6R complex (hyper-IL6) binds to IL6ST/gp130 on cell surfaces and induces signaling also on cells that do not express membrane-bound IL6R in a process called IL6 'trans-signaling'. sIL6R is causative for the pro-inflammatory properties of IL6 and an important player in the development of chronic inflammatory diseases . In complex with IL6, is required for induction of VEGF production . Plays a protective role during liver injury, being required for maintenance of tissue regeneration (By similarity). 'Trans-signaling' in central nervous system regulates energy and glucose homeostasis (By similarity). .; FUNCTION: [Soluble interleukin-6 receptor subunit alpha]: Soluble form of IL6 receptor (sIL6R) that acts as an agonist of IL6 activity . The IL6:sIL6R complex (hyper-IL6) binds to IL6ST/gp130 on cell surfaces and induces signaling also on cells that do not express membrane-bound IL6R in a process called IL6 'trans-signaling'. sIL6R is causative for the pro-inflammatory properties of IL6 and an important player in the development of chronic inflammatory diseases . In complex with IL6, is required for induction of VEGF production . Plays a protective role during liver injury, being required for maintenance of tissue regeneration (By similarity). 'Trans-signaling' in central nervous system regulates energy and glucose homeostasis (By similarity). . |
Accessions | H0Y9B1 ENST00000344086.8 [P08887-2] H0Y949 P08887 ENST00000368485.8 [P08887-1] ENST00000515190.1 A0N0L5 D6R9R8 A0A087WTB5 ENST00000512471.1 ENST00000622330.5 ENST00000476006.5 |